Skip to main content
. 2016 Jun 29;16(12):900–915. doi: 10.14744/AnatolJCardiol.2016.6755

Table 6.

Discharge medications

STEMI (n=514) UA/NSTEMI (n=520)
Antiplatelets, n (%)
 ASA 508 (98.8) 509 (97.9)
 Clopidogrel 478 (93.0) 419 (80.6)
Combined ASA/clopidogrel use
  ASA only 36 (7.0) 97 (18.7)
  Clopidogrel only 6 (1.2) 7 (1.3)
  ASA + Clopidogrel 472 (91.8) 412 (79.2)
  Neither 0 (0.0) 4 (0.8)
 Ticlopidine 23 (4.5) 6 (1.2)
 Other antiplatelet 3 (0.6) 1 (0.2)
By stent placement during PCI
 YES 434 (84.4) 276 (53.1)
  ASA 428 (98.6) 273 (98.9)
  Clopidogrel 415 (95.6) 270 (97.8)
  Ticlopidine 18 (4.1) 5 (1.8)
  Other antiplatelet 3 (0.7) 0 (0.0)
 NO 80 (15.6) 244 (46.9)
  ASA 80 (100) 236 (96.7)
 Clopidogrel 63 (78.8) 149 (61.1)
 Ticlopidine 5 (6.3) 1 (0.4)
 Other antiplatelet 0 (0.0) 1 (0.4)
 Anticoagulants (Acenocoumarol/Warfarin) 2 (0.4) 3 (0.6)
Other CV therapies
 Beta blockers 466 (90.7) 466 (89.6)
 ACE/ARB inhibitors 439 (85.4) 413 (79.4)
Lipid lowering drugs
  Total 463 (90.1) 460 (88.5)
  Atorvastatin 337 (65.6) 307 (59.0)
  Pravastatin 1 (0.2) 2 (0.4)
  Rosuvastatin 122 (23.7) 145 (27.9)
  Simvastatin 1 (0.2) 2 (0.4)
  Other 5 (1.0) 6 (1.2)
 Diuretics 48 (9.3) 42 (8.1)
 Aldosterone inhibitors 41 (8.0) 14 (2.7)
 Ca-channel blocker 26 (5.1) 60 (11.5)
Non-CV therapies
 PPIs
 Total 175 (34.0) 155 (29.8)
 Omeprazole 26 (5.1) 8 (1.5)
 Pantoprazole 99 (19.3) 106 (20.4)
 Rabeprazole 2 (0.4) 1 (0.2)
 Esomeprazole 2 (0.4) 9 (1.7)
 Lansoprazole 47 (9.1) 31 (6.0)
 H2-receptor antagonist 78 (15.2) 66 (12.7)
 NSAIDs (traditional and coxibs) 1 (0.2) 2 (0.4)

ACE - angiotensin-converting-enzyme inhibitor; ARB - angiotensin receptor blockers; ASA - acetylsalicylic acid; Ca - calcium; CV - cardiovascular; NSAIDs - non-steroidal anti-inflammatory drugs; NSTEMI - non-ST-segment elevation myocardial infarction; PCI - percutaneous coronary intervention; PPIs - proton pump inhibitors; STEMI – Stsegment elevation myocardial infarction; UA - unstable angina